Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial
…, D van der Heijde, G Citera, A Elegbe… - Annals of the …, 2014 - ard.bmj.com
Objectives To compare over 2 years the safety, efficacy and radiographic outcomes of
subcutaneous abatacept versus adalimumab, in combination with methotrexate (MTX), in patients …
subcutaneous abatacept versus adalimumab, in combination with methotrexate (MTX), in patients …
Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results …
…, C Rodriguez, I Delaet, A Elegbe… - Arthritis care & …, 2013 - Wiley Online Library
Objective To evaluate the impact of concomitant methotrexate (MTX) on subcutaneous (SC)
abatacept immunogenicity, and to assess safety and efficacy. Methods This phase III, open‐…
abatacept immunogenicity, and to assess safety and efficacy. Methods This phase III, open‐…
Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor …
…, M Luggen, M Le Bars, R Aranda, A Elegbe… - The Journal of …, 2012 - jrheum.org
Objective. To evaluate abatacept safety and efficacy over 5 years in patients with rheumatoid
arthritis (RA) who had inadequate response to anti-tumor necrosis factor (TNF) therapy in …
arthritis (RA) who had inadequate response to anti-tumor necrosis factor (TNF) therapy in …
Longterm safety and efficacy of subcutaneous abatacept in patients with rheumatoid arthritis: 5-year results from a phase IIIb trial
…, CW Legerton, E Nasonov, P Durez, A Elegbe… - The Journal of …, 2018 - jrheum.org
Objective. To assess 5-year safety, tolerability, and efficacy of subcutaneous (SC) abatacept
(ABA) in methotrexate (MTX)-refractory patients with rheumatoid arthritis (RA). Methods. The …
(ABA) in methotrexate (MTX)-refractory patients with rheumatoid arthritis (RA). Methods. The …
[HTML][HTML] Randomized clinical trial design to assess abatacept in resistant nephrotic syndrome
…, JB Kopp, J Sedor, S Overfield, A Elegbe… - Kidney International …, 2018 - Elsevier
Introduction Treatment-resistant nephrotic syndrome is a rare form of glomerular disease
that occurs in children and adults. No Food and Drug Administration−approved treatments …
that occurs in children and adults. No Food and Drug Administration−approved treatments …
Improvements in patient‐reported outcomes after treatment with deucravacitinib in patients with psoriatic arthritis: results from a randomized phase 2 trial
…, J Zhuo, T Lehman, M Nowak, A Elegbe… - Arthritis Care & …, 2024 - Wiley Online Library
Objective Deucravacitinib, a TYK‐2 inhibitor, was assessed in a phase 2 trial in patients
with active psoriatic arthritis (PsA). Here, we report effects of deucravacitinib from the patient …
with active psoriatic arthritis (PsA). Here, we report effects of deucravacitinib from the patient …
P038 ozanimod first-dose cardiac effects in patients with moderately to severely active ulcerative colitis and relapsing multiple sclerosis
…, A Pai, H Ahmad, L Charles, A Elegbe… - Official journal of the …, 2021 - journals.lww.com
BACKGROUND: Ozanimod, an oral sphingosine 1-phosphate (S1P) receptor modulator
that selectively targets S1P 1 and S1P 5, is approved in the US for treating moderately to …
that selectively targets S1P 1 and S1P 5, is approved in the US for treating moderately to …
A phase 3 randomized study of neoadjuvant chemotherapy (NAC) alone or in combination with nivolumab (NIVO)±BMS-986205 in cisplatin-eligible muscle invasive …
…, MS Van Der Heijden, N Garzon, A Elegbe… - 2019 - ascopubs.org
TPS4587 Background: Immuno-oncology (IO) therapies have revolutionized the treatment (tx)
of pts with advanced bladder cancer (advBC). For pts with cisplatin-eligible MIBC, the …
of pts with advanced bladder cancer (advBC). For pts with cisplatin-eligible MIBC, the …
A phase II, randomized study of nivolumab (nivo) or nivo plus BMS-986205 with or without intravesical Bacillus Calmette-Guerin (BCG) in BCG-unresponsive, high-risk …
…, H Nishiyama, J Palou Redorta, JA Taylor, A Elegbe… - 2019 - ascopubs.org
TPS493 Background: Immune checkpoint inhibitors, including nivo (anti–PD-1), have
demonstrated favorable tolerability and efficacy profiles, ushering in a new treatment (tx) paradigm …
demonstrated favorable tolerability and efficacy profiles, ushering in a new treatment (tx) paradigm …
S730 Ozanimod Is an Efficacious Oral Therapy After 5-ASA Failure in Immunomodulator-and Biologic-Naive Patients With Ulcerative Colitis: Post Hoc Analysis From …
…, M Osterman, AK Petersen, A Elegbe… - Official journal of the …, 2022 - journals.lww.com
Methods: TN consisted of a 10-week induction period. Pts in Cohort (C) 1, stratified by CS
use at screening, were randomized to OZA 0.92 mg (equivalent to OZA HCl 1 mg; n= 429) or …
use at screening, were randomized to OZA 0.92 mg (equivalent to OZA HCl 1 mg; n= 429) or …